• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Saturday, May 27, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

CNIO researchers clarify the role of the two isoforms of KRAS, the most common oncogene in humans

Bioengineer by Bioengineer
July 19, 2021
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

These findings suggest that for therapies to be effective, they must be targeted at both gene products

IMAGE

Credit: CNIO

KRAS was one of the first oncogenes to be identified, a few decades ago. It is among the most common drivers of cancer and its mutations can be detected in around 25 per cent of human tumours. The development of KRAS inhibitors is, thus, an extremely active line of research. Effective results have been elusive so far, though – no KRAS inhibitor had been available until a month ago, when the FDA granted approval to Sotorasib.

KRAS encodes two gene products, KRAS4A and KRAS4B, whose levels can vary across organs and embryonic stages. When KRAS mutates, both variants, or isoforms, are activated. Though, some studies have focussed on approaches to target only KRAS4B, since it usually found to be expressed at higher levels in tumours.

In this study, Matthias Drosten, Marina Salmón and Guillem Paniagua of the Experimental Oncology Programme, headed by Mariano Barbacid at the CNIO, had a more fundamental goal: to understand how the isoforms work separately. As they state in the paper to be published in PNAS, “The biological relevance of the expression of two isoforms has puzzled researchers for decades.”

Lung cancer and metastasis

A basic research project in principle, Drosten and Salmón’s study produced results that came as “a surprise.” Even though KRAS4B is the dominant form in cancer, the KRAS4A mutant is also oncogenic, and it is even more active.

In the words of the authors, “KRAS4AG12V alone, in the absence of KRAS4B, can induce lung cancer and metastasis in 20 percent of individuals. Our results suggest that for therapies to be effective, the two KRAS isoforms should be targeted.”

KRAS genes in embryonic development

The researchers at the CNIO created two genetically engineered mouse models that lacked KRAS4B and expressed the KRAS4A variant only, both with and without the G12V mutation (KRAS4AG12V).

In addition, the study explored the role of the two isoforms in embryonic development. One of them, KRAS4B, “is key after birth, since in the absence of this variant, mice cannot grow as a result of heart disease”.

The CNIO Experimental Oncology Group is a global reference studying KRAS-related cancers, with notable examples such as the elimination of lung tumors and advanced pancreatic tumors by inactivating the RAF1 kinase in animal models.

###

In this work Sagrario Ortega, head of the Mouse Genomic Editing Core Unit at the CNIO, Javier Muñoz, head of the CNIO Proteomics Core Unit and Eduardo Caleiras of the Histopathology Core Unit at the CNIO, contributed fundamentally. The research was funded by the Spanish Ministry of Science and Innovation, the Institute of Health Carlos III, the European Research Council (ERC), the Autonomous Community of Madrid, the Fundación CRIS Cancer and AXA Research Fund.

Media Contact
Department of Communications
[email protected]

Related Journal Article

http://dx.doi.org/10.1073/pnas.2023112118

Tags: BiologycancerCell BiologyClinical TrialsDisease in the Developing WorldGenesGeneticsHealth ProfessionalsMolecular Biology
Share12Tweet8Share2ShareShareShare2

Related Posts

Achala Vagal

Study finds distinct patterns of pre-existing brain health characteristics in stroke patients

May 27, 2023
Production of a biomedical microfibre

Basis for skin and organ production: Researchers from Graz University of Technology revolutionize production of biocompatible microfibers

May 26, 2023

A detailed map of Urban Heat Islands

May 26, 2023

How eating natto might help to distress

May 26, 2023
Please login to join discussion

POPULAR NEWS

  • the University of Haifa

    Groundbreaking study uncovers first evidence of long-term directionality in the origination of human mutation, fundamentally challenging Neo-Darwinism

    115 shares
    Share 46 Tweet 29
  • How life and geology worked together to forge Earth’s nutrient rich crust

    35 shares
    Share 14 Tweet 9
  • Element creation in the lab deepens understanding of surface explosions on neutron stars

    34 shares
    Share 14 Tweet 9
  • The case for engineering our food

    73 shares
    Share 29 Tweet 18

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Study finds distinct patterns of pre-existing brain health characteristics in stroke patients

New moms and dads left unprepared for parenthood by government health ‘failures’, report warns

Absolute vs. relative efficiency: How efficient are blue LEDs, actually?

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 50 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In